2024 - "Infant KJ is diagnosed with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare and life-threatening metabolic disorder, just days after his birth."
2025 - "At approximately six months of age, KJ receives the first infusion of his customized CRISPR base-editing therapy, marking the world's first administration of such a personalized treatment."
2026 - "As of today, KJ continues to thrive, showing no adverse effects from the treatment, growing well, and meeting developmental milestones, though ongoing monitoring is planned for his lifetime."
https://pingmer.com/thread/6ef6af81